$60MSeries A, 29 January 2026
The company emerged from stealth to advance its small molecule and antibody-drug conjugate cancer pipeline.
- Amount
- $60M
- Stage
- Series A
- Announced
- 29 January 2026
- Use of funds
- The company emerged from stealth to advance its small molecule and antibody-drug conjugate cancer pipeline.
- Checked
- Announced by the company
- Sources
- Breakthru Medicine emerges from stealth with $60M Series A biospace.com
Breakthru Medicine emerges from stealth with $60M Series A pulse2.com